Skip to content
Homepage
Clinic directory

Clinics in Brentwood, Missouri

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Brentwood, MO

Stem Cell Therapy clinics in Brentwood

Brentwood supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Williamson Medical Center and nearby Vanderbilt, and stem cell practice in the area spans Maryland Farms, Cool Springs border, and the Franklin Road corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Tennessee passed the Regenerative Medicine Act in 2017, which recognizes adult stem cell therapies and requires informed consent and outcome reporting. Nashville and Memphis clinics operate under both state law and federal 21 CFR Part 1271 rules. The Tennessee Board of Medical Examiners oversees physician practice. The 3 Brentwood clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Tennessee Board of Medical Examiners licensure checks.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on Missouri's stem cell therapy rules.

Missouri cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Missouri for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Missouri's regenerative medicine market is concentrated in St Louis and Kansas City.

  • Missouri Medical Practice Act, Missouri Revised Statutes Chapter 334
    Establishes physician licensure and discipline through the Missouri State Board of Registration for the Healing Arts.
  • Missouri Pharmacy Practice Act, Missouri Revised Statutes Chapter 338
    Regulates compounding pharmacies aligned with federal 503A and 503B standards.
  • Missouri Merchandising Practices Act, Missouri Revised Statutes Chapter 407
    Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims, including against healthcare providers.

The FDA has issued warning letters to Missouri clinics offering stem cell and exosome therapies. The Missouri State Board of Registration for the Healing Arts has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Missouri Attorney General has used the Merchandising Practices Act to pursue clinics making unsupported clinical claims, and the MMPA also enables private class actions. Class-action suits against Missouri stem cell clinics have produced settlements. Federal warning letters apply nationally and Missouri clinics face direct exposure.

Stem Cell Therapy in Brentwood, answered.

Most stem cell therapies at private Brentwood clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Tennessee passed the Regenerative Medicine Act in 2017, which recognizes adult stem cell therapies and requires informed consent and outcome reporting.

In the Brentwood metro, single-joint autologous bone marrow or adipose injections typically run $4,000 to $12,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $8,000 to $20,000, and full multi-session protocols can reach $15,000 to $40,000. Exosome add-ons range $3,500 to $7,500. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Brentwood clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at Williamson Medical Center and nearby Vanderbilt periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Brentwood or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the Tennessee Board of Medical Examiners and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with Regenerative Medicine Act 2017.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology